 |
Organized by
Xosé R. Bustelo, Jorge Moscat and Tak W. Mak
Important advances have occurred during these last years on the understanding of
the signaling, metabolic, epigenetic, and genetic changes that occur in tumor cells.
In addition, better views have been obtained on the sociobiology of the cancer cell
in relation to its surrounding transformed counterparts, stromal cells, and immune
cells. These advances have translated into a holistic view of the main biological
processes that are important for the development of the tumorigenic phenotype.
As a result, we are now in an excellent condition to apply these advances in issues
of clinical interest, such as the development of better diagnostic and prognostic
tools and, for the first time in the history of biomedicine, the design of new anti-
tumoral therapies aiming at blocking specific molecular targets of cancer cells. In
this context, this workshop is intended to provide a format for the exchange of ideas
and information, to discuss the latest research findings and methodological advances,
and to foster interactions amongst groups active in diverse systems related to the
molecular biology and pathophysiology of the cancer cell. Special topics of attention
will be those related to the discussion of the different signal transduction pathways
that contribute to the malignancy of the cancer cell, the manipulation of the
metabolome by cancer cells, the processes of senescence and genetic instability,
and the cell-cell relationships that are established during tumor progression among
malignant cells, stromal cells and the immune system.
Speakers include:
Linda Van Aelst
Cold Spring Harbor Lab., Cold Spring Harbor,
NY (USA)
Dario Alessi
University of Dundee, Dundee (UK)
Frances Balkwill
Institute of Cancer Res., London (UK)
Dafna Bar-Sagi
New York Univ., New York, NY (USA)
Johaness L. Bos
Univ. Medi. Cent., Utrecht (The Netherlands)
Xosé R. Bustelo
Centro Inv. del Cancer, Salamanca (Spain)
Judith Campisi
Lawrence Berkeley Lab., Berkeley, CA (USA)
Navdeep S. Chandel
Northwestern Univ., Chicago, IL (USA)
Sankar Ghosh
Yale University, New Haven, CT (USA)
Amato J. Giaccia
Stanford University, Stanford, CA (USA)
Eyal Gottlieb
Cancer Research UK, Glasgow (UK)
Douglas R. Green
St. Jude Chidren’s Hosp., Menphis, TN (USA)
Jan H. J. Hoeijmakers
Erasmus Med. Cent., Rotterdam (The Netherlands)
Guillermina Lozano
Univesity of Texas, Huston, TX (USA)
Tak W. Mak
Princess Margaret Hosp., Toronto, ON (Canada)
Chris Marshall
Institute of Cancer Res., London (UK)
Jorge Moscat
Univ. of Cincinnati, Cincinnati, OH (USA)
Benjamin Neel
B. I. D. Medical Center, Boston, MA (USA)
Pier Giuseppe Pelicci
European Inst. of Oncology, Milan (Italy)
Jeffrey W. Pollard
Yeshiva University, New York, NY (USA)
David M. Sabatini
Whitehead Institute, Cambridge, MA (USA)
M. Celeste Simon
Univ. of Pennsylvania, Philadelphia, PA (USA)
Bruce Spiegelman
Dana Farber Cancer Institute, Boston, MA (USA)
George Thomas
Univ. of Cincinnati, Cincinnati, OH (USA)
Jenny Ting
Univ. of North Carolina, Chapel Hill, NC (USA)
Further info
|
|
